Skip to Content
Merck
CN
All Photos(1)

Documents

382129

Millipore

HIV Reverse Transcriptase, Recombinant, E. coli

liquid, ≥5,000 units/mg protein, Nuclease-free

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
HIV RT
UNSPSC Code:
12352202
NACRES:
NA.54

recombinant

expressed in E. coli

Quality Level

100

form

liquid

specific activity

≥10,000 units/mL
≥5,000 units/mg protein

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

technique(s)

molecular cloning: suitable

foreign activity

Nuclease-free

shipped in

wet ice

storage temp.

−20°C

General description

Recombinant HIV reverse transcriptase expressed in E. coli. Catalyzes error-prone synthesis on DNA and RNA templates. Provides an excellent target for evaluating antiviral agents.

Application

HIV Reverse Transcriptase, Recombinant, E.coli has been used as a standard in reverse transcriptase activity assay.

Packaging

Please refer to vial label for lot-specific concentration.

Warning

Toxicity: Standard Handling (A)

Unit Definition

One unit is defined as the amount of enzyme that will incorporate 1.0 nmol of labeled dTTP into acid-insoluble material in 20 min at 37°C, pH 8.3.

Physical form

In 10 mM potassium phosphate, 1 mM DTT, 20% glycerol, pH 7.4.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Geraldine Vilmen et al.
mBio, e0275221-e0275221 (2022-01-12)
Infection of rhesus macaques with simian-human immunodeficiency viruses (SHIVs) is the preferred model system for vaccine development because SHIVs encode human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs)-a key target of HIV-1 neutralizing antibodies. Since the goal of vaccines
Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly
Reed JC, et al.
Journal of Virology, 95(3), 10-1128 (2021)
Conformation of HIV-1 Envelope governs rhesus CD4 usage and simian-human immunodeficiency virus replication
Vilmen G, et al.
mBio, 13(1), e02752-e02721 (2022)
Bo Meng et al.
Cell reports, 35(13), 109292-109292 (2021-06-25)
We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K and Y453F, known to increase binding affinity to the ACE2 receptor and confer
Jonathan C Reed et al.
Journal of virology, 95(3) (2020-11-06)
Given the projected increase in multidrug-resistant HIV-1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host-targeting compounds are of particular interest because they can offer

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service